Research Article

Quantitative Structure Activity Relationship Studies of Topoisomerase I Inhibitors as Potent Antibreast Cancer Agents

Table 1

Structures of the indenoisoquinoline derivatives as topoisomerase I inhibitors.

849793.tab.001

CompoundR1R2R3R4Activity, GI50 ( M)

1_3–H–NO2849793.tab.002–OCH33.24
1_4–H–NO2849793.tab.003–OCH30.251
1_5–H–NO2849793.tab.004–OCH33.31
1_35–H–NO2849793.tab.005a849793.tab.005b30.9
1_38–H–NO2849793.tab.006–SMe30.9
1_40–H–NO2849793.tab.007–H31.6
1_41–H–NO2849793.tab.008–F37.2
1_42–H–NO2849793.tab.009–Cl14.8
1_43–H–NO2849793.tab.0010–Br0.282
1_49–H–NO2849793.tab.0011849793.tab.0011b83.2
1_50–H–NO2849793.tab.0012a849793.tab.0012b39.8
1_53–H–NO2849793.tab.0013a849793.tab.0013b6.03
1_56–H–NO2849793.tab.0014–F2.88
1_59–H–NO2849793.tab.0015–I34.7
1_62–H–NO2849793.tab.0016a849793.tab.0016b0.200
1_63–H–NO2849793.tab.0017–C2H51.55
1_64–H–NO2849793.tab.0018–CH30.316
1_65–H–NO2849793.tab.0019a849793.tab.0019b0.204
1_66–H–NO2849793.tab.0020a849793.tab.0020b0.468
1_67–H–NO2849793.tab.0021–H0.123
1_68–H–NO2849793.tab.0022–F0.081
1_70–H–NO2849793.tab.0023–Br0.162
1_71–H–NO2849793.tab.0024–I0.224
1_86–OCH3–OCH3849793.tab.0025a849793.tab.0025b13.8
1_87–OCH3–OCH3849793.tab.0026a849793.tab.0026b37.2
1_90–OCH3OCH3849793.tab.0027–F43.7
1_94–OCH3OCH3849793.tab.0028a849793.tab.0028b50.1
1_95–OCH3OCH3849793.tab.0029–NH20.214
1_99–OCH3OCH3849793.tab.0030–H9.77
1_100–OCH3OCH3849793.tab.0031–F38.0
1_104–OCH3OCH3849793.tab.0032–NH24.17
1_105–OCH3OCH3849793.tab.0033–N(CH3)217.8
1_106–OCH3OCH3849793.tab.0034a849793.tab.0034b1.70
1_107–OCH3OCH3849793.tab.0035–C2H52.00
1_108–OCH3OCH3849793.tab.0036–H0.631
1_109–OCH3–OCH3849793.tab.0037–F6.03
1_110–OCH3–OCH3849793.tab.0038a849793.tab.0038b18.2
1_111–OCH3–OCH3849793.tab.0039a849793.tab.0039b18.6
1_112–OCH3–OCH3849793.tab.0040–NO215.8